Over the past 12 months, 13 insiders at Verona Pharma plc filed 13 open-market SEC Form 4 transactions on VRNA: 0 purchases worth $0 and 13 sales worth $7.1M. Insiders have been net sellers over this period. The most recent filing was on Aug 1, 25.
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| Aug 1, 25 | Christina AckermannDirector | SELL | 1.8K | $13.14 | $24K |
| Aug 1, 25 | Michael AustwickDirector | SELL | 11.3K | $13.14 | $148K |
| Aug 1, 25 | James Aloysius BradyDirector | SELL | 824 | $13.14 | $11K |
| Aug 1, 25 | Kenneth CunninghamDirector | SELL | 10.8K | $13.14 | $142K |
| Aug 1, 25 | Lisa DeschampsDirector | SELL | 9.5K | $13.14 | $124K |
| Aug 1, 25 | David R EbsworthDirector | SELL | 1.9K | $13.14 | $25K |
| Aug 1, 25 | Martin EdwardsDirector | SELL | 10.8K | $13.14 | $142K |
| Aug 1, 25 | Andrew FisherGeneral Counsel | SELL | 9.6K | $13.14 | $126K |
| Aug 1, 25 | Mark W HahnChief Financial Officer | SELL | 208.9K | $13.14 | $2.7M |
| Aug 1, 25 | Kathleen A. RickardChief Medical Officer | SELL | 58.3K | $13.14 | $767K |
| Aug 1, 25 | Mahendra ShahDirector | SELL | 3.6K | $13.14 | $47K |
| Aug 1, 25 | Vikas SinhaDirector | SELL | 4.3K | $13.14 | $57K |
| Aug 1, 25 | David ZaccardelliPresident and CEO | SELL | 208.9K | $13.14 | $2.7M |
| Jun 16, 25 | Andrew FisherGeneral Counsel | SELL | 80.0K | $11.53 | $922K |
| Jun 11, 25 | Mark W HahnChief Financial Officer | SELL | 400.0K | $11.40 | $4.6M |
| Jun 11, 25 | David ZaccardelliPresident and CEO | SELL | 400.0K | $11.40 | $4.6M |
| May 29, 25 | Mark W HahnChief Financial Officer | SELL | 204.9K | $9.33 | $1.9M |
| May 29, 25 | David ZaccardelliPresident and CEO | SELL | 208.7K | $9.33 | $1.9M |
| May 28, 25 | Mark W HahnChief Financial Officer | SELL | 162.7K | $9.30 | $1.5M |
| May 28, 25 | David ZaccardelliPresident and CEO | SELL | 157.7K | $9.30 | $1.5M |
| May 27, 25 | Mark W HahnChief Financial Officer | SELL | 32.4K | $9.53 | $309K |
| May 27, 25 | David ZaccardelliPresident and CEO | SELL | 33.6K | $9.53 | $320K |
| May 20, 25 | Vikas SinhaDirector | SELL | 160.0K | $9.39 | $1.5M |
| May 15, 25 | Andrew FisherGeneral Counsel | SELL | 80.0K | $8.57 | $686K |
| May 14, 25 | Christina AckermannDirector | SELL | 40.0K | $8.44 | $338K |
| May 6, 25 | Kathleen A. RickardChief Medical Officer | SELL | 115.0K | $8.82 | $1.0M |
| May 2, 25 | Mark W HahnChief Financial Officer | SELL | 400.0K | $9.09 | $3.6M |
| May 2, 25 | David ZaccardelliPresident and CEO | SELL | 400.0K | $9.09 | $3.6M |
| May 1, 25 | Mark W HahnChief Financial Officer | SELL | 108.3K | $8.95 | $969K |
| May 1, 25 | Kathleen A. RickardChief Medical Officer | SELL | 27.3K | $8.95 | $245K |
| May 1, 25 | David ZaccardelliPresident and CEO | SELL | 108.3K | $8.95 | $969K |
| Apr 29, 25 | Vikas SinhaDirector | SELL | 120.4K | $8.92 | $1.1M |
| Apr 29, 25 | Andrew FisherGeneral Counsel | SELL | 26.1K | $8.98 | $234K |
| Apr 29, 25 | Mark W HahnChief Financial Officer | SELL | 90.4K | $8.98 | $811K |
| Apr 29, 25 | Kathleen A. RickardChief Medical Officer | SELL | 34.4K | $8.98 | $309K |
| Apr 29, 25 | David ZaccardelliPresident and CEO | SELL | 90.4K | $8.98 | $811K |
| Mar 12, 25 | Kathleen A. RickardChief Medical Officer | SELL | 79.3K | $8.35 | $662K |
| Dec 6, 24 | Mark W HahnChief Financial Officer | SELL | 183.7K | $5.01 | $920K |
| Dec 6, 24 | David ZaccardelliPresident and CEO | SELL | 162.8K | $5.01 | $816K |
| Dec 5, 24 | Mark W HahnChief Financial Officer | SELL | 640.0K | $5.01 | $3.2M |
| Dec 5, 24 | David ZaccardelliPresident and CEO | SELL | 640.3K | $5.01 | $3.2M |
| Dec 4, 24 | Mark W HahnChief Financial Officer | SELL | 58.2K | $5.00 | $291K |
| Dec 4, 24 | David ZaccardelliPresident and CEO | SELL | 67.6K | $5.00 | $338K |
| Dec 2, 24 | Mark W HahnChief Financial Officer | SELL | 1.6K | $5.00 | $8K |
| Dec 2, 24 | David ZaccardelliPresident and CEO | SELL | 3.2K | $5.00 | $16K |
| Nov 29, 24 | Mark W HahnChief Financial Officer | SELL | 98.7K | $5.01 | $495K |
| Nov 29, 24 | David ZaccardelliPresident and CEO | SELL | 98.9K | $5.01 | $495K |
| Nov 27, 24 | Mark W HahnChief Financial Officer | SELL | 12.9K | $5.00 | $65K |
| Nov 27, 24 | David ZaccardelliPresident and CEO | SELL | 23.2K | $5.00 | $116K |
| Nov 26, 24 | Mark W HahnChief Financial Officer | SELL | 800 | $5.00 | $4K |
Over the past 12 months, insiders at Verona Pharma plc filed 0 open-market purchases worth $0 and 13 sales worth $7.1M on VRNA, which makes them net sellers over the period. The most recent Form 4 was filed on Aug 1, 25.
13 different insiders at Verona Pharma plc filed open-market SEC Form 4 transactions on VRNA over the last 12 months.
InsiderTape plots every VRNA insider buy and sell directly on the price chart and flags new SEC Form 4 filings as they arrive, with cluster detection and buy/sell pressure. The data updates daily from SEC EDGAR.
InsiderTape plots every Verona Pharma plc insider buy and sell on the price chart, with buy/sell pressure, cluster detection, and alerts the moment new Form 4s hit. Start a free 7-day trial, cancel anytime.
Does it work? In five years of data, insider clusters beat the Russell 2000 about 60% of the time and the CFO's buy was the sharpest signal of all. See the backtest →
START FREE TRIAL →